6-Apr-2026
Bausch Health to Announce First Quarter 2026 Results on April 29, 2026
PRNewswire (Tue, 31-Mar 7:00 AM ET)
Bausch Health Announces Ortho Dermatologics 2026 ASPIRE HIGHER Scholarship Program
PRNewswire (Thu, 26-Mar 8:00 AM ET)
Bausch Health's OraPharma Celebrates 25 Years of ARESTIN (minocycline HCl) Microspheres
PRNewswire (Thu, 19-Feb 8:00 AM ET)
Bausch Health Announces 2026 Gastrointestinal Health Scholars Program
PRNewswire (Wed, 11-Feb 8:00 AM ET)
Market Chameleon (Fri, 23-Jan 3:09 AM ET)
Bausch Health Provides Update on RED-C Phase 3 Clinical Trials
PRNewswire (Fri, 23-Jan 7:45 AM ET)
Bausch Health to Announce Fourth Quarter and Full Year 2025 Results on February 18, 2026
PRNewswire (Wed, 21-Jan 7:00 AM ET)
Market Chameleon (Mon, 1-Dec 6:06 AM ET)
Market Chameleon (Thu, 30-Oct 7:30 AM ET)
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
Bausch Health Companies trades on the NYSE stock market under the symbol BHC.
As of April 6, 2026, BHC stock price climbed to $5.41 with 644,011 million shares trading.
BHC has a beta of 1.39, meaning it tends to be more sensitive to market movements. BHC has a correlation of 0.12 to the broad based SPY ETF.
BHC has a market cap of $2.00 billion. This is considered a Mid Cap stock.
Last quarter Bausch Health Companies reported $3 billion in Revenue and $1.10 earnings per share. This beat revenue expectation by $91 million and missed earnings estimates by -$.14.
In the last 3 years, BHC traded as high as $11.46 and as low as $3.96.
The top ETF exchange traded funds that BHC belongs to (by Net Assets): DFIS, DISV, PPH, DFIC, DFAX.
BHC has underperformed the market in the last year with a return of -11.5%, while the SPY ETF gained +18.0%. In the last 3 month period, BHC fell short of the market, returning -25.0%, while SPY returned -3.3%. However, in the most recent 2 weeks BHC has outperformed the stock market by returning +7.6%, while SPY returned +0.4%.
BHC support price is $5.19 and resistance is $5.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BHC shares will trade within this expected range on the day.